Citations

Clear

1446 citation(s) found for "Howard, F".

Genome-Wide Gene–Diabetes and Gene–Obesity Interaction Scan in 8,255 Cases and 11,900 Controls from PanScan and PanC4 Consortia
Tang, Hongwei, Jiang, Lai , Arslan, Alan A. , Bracci, Paige M. , Brennan, Paul , Canzian, Federico , Du, Mengmeng , Gallinger, Steven , Goodman, Phyllis J. , Visvanathan, Kala , Andreotti, Gabriella , Babić, Ana , Berndt, Sonja I. , Bueno‐de‐Mesquita, Bas , Buring, Julie E. , Campa, Daniele , Childs, Erica J., Fuchs, Charles S. , Gaziano, J. Michael , Hartge, Patricia, Hassam, Manal H., Holly, Elizabeth A. , Hoover, Robert N. , Hung, Rayjean J. , Kurtz, Robert C. , Lee, I-Min, Ng, Kimmie , Oberg, Ann L. , Peters, Ulrike , Porta, Miquel , Rabe, Kari G. , Rothman, Nathaniel , Scélo, Ghislaine , Sesso, Howard D. , Thompson, Ian M. , Tjønneland, Anne , Trichopoulou, Antonia , Wactawski‐Wende, Jean , Wentzensen, Nicolas , Zeleniuch‐Jacquotte, Anne , Jacobs, Eric J. , Petersen, Gloria M. , Wolpin, Brian M. , Chatterjee, Nilanjan , Li, Donghui , Arslan, Alan A , Brennan, Paul , Canzian, Federico , Bamlet, William R , Blackford, Amanda , Duell, Eric J , Hung, Rayjean J , Malats, Nuria , Milne, Roger L , Oberg, Ann L , Orlow, Irene , Sesso, Howard D , Tjønneland, Anne , Wactawski-Wende, Jean , Yu, Herbert , Amundadottir, Laufey , Klein, Alison P , Li, Donghui , Chaffee, Kari G. , Visvanathan, Kala , Porta, Miquel , Thompson, Ian M , Zeleniuch-Jacquotte, Anne , Stolzenberg‐Solomon, Rachael Z. , Freeman, Laura E. Beane , Giles, Graham G. , Kooperberg, Charles , Marchand, Loı̈c Le , Neale, Rachel Ε. , Shu, Xiao‐Ou , White, Emily , Zheng, Wei , Albanes, Demetrius , Bamlet, William R. , Chanock, Stephen Jacob , Duell, Eric J. , Goggins, Michael , Malats, Núria , Milne, Roger L. , Orlow, Irene , Rothman, Nathaniel , Silverman, Debra T. , Wilkens, Lynne R. , Yu, Kai , Ámundadóttir, Laufey T. , Risch, Harvey A. , Klein, Alison P. , Kraft, Peter , Wei, Peng

Mayo Clinic

Cancer Epidemiology, Biomarkers & Prevention | June 16, 2020 | Volume: 29 | Issue: 9 | Pages: 1784-1791

10.1158/1055-9965.epi-20-0275 | PMID 32546605 Get It

Abstract Background: Obesity and diabetes are major modifiable risk factors for pancreatic cancer. Interactions between genetic variants and diabetes/obesity have not previously been comprehensively investigated in pancreatic cancer at the genome-wide level. Methods: We conducted a gene–environment interaction (GxE) analysis including 8,255 cases and 11,900 controls from four pancreatic cancer genome-wide association study (GWAS) datasets (Pancreatic Cancer Cohort Consortium I–III and Pancreatic Cancer Case Control Consortium). Obesity (body mass index ≥30 kg/m2) and diabetes (duration ≥3 years) were the environmental variables of interest. Approximately 870,000 SNPs (minor allele frequency ≥0.005, genotyped in at least one dataset) were analyzed. Case–control (CC), case-only (CO), and joint-effect test methods were used for SNP-level GxE analysis. As a complementary approach, gene-based GxE analysis was also performed. Age, sex, study site, and principal components accounting for population substructure were included as covariates. Meta-analysis was applied to combine individual GWAS summary statistics. Results: No genome-wide significant interactions (departures from a log-additive odds model) with diabetes or obesity were detected at the SNP level by the CC or CO approaches. The joint-effect test detected numerous genome-wide significant GxE signals in the GWAS main effects top hit regions, but the significance diminished after adjusting for the GWAS top hits. In the gene-based analysis, a significant interaction of diabetes with variants in the FAM63A (family with sequence similarity 63 member A) gene (significance threshold P < 1.25 × 10−6) was observed in the meta-analysis (PGxE = 1.2 ×10−6, PJoint = 4.2 ×10−7). Conclusions: This analysis did not find significant GxE interactions at the SNP level but found one significant interaction with diabetes at the gene level. A larger sample size might unveil additional genetic factors via GxE scans. Impact: This study may contribute to discovering the mechanism of diabetes-associated pancreatic cancer.
Implementation of Germline Testing for Prostate Cancer: Philadelphia Prostate Cancer Consensus Conference 2019
Kelly, William Kevin, Cheng, Heather H. , Cookson, Michael S. , Dahut, William L. , Weissman, Scott M., Soule, Howard R. , Petrylak, Daniel P. , Dicker, Adam P. , AlDubayan, Saud H. , Pettaway, Curtis A. , Daly, Mary B., Mohler, James L. , Parsons, J. Kellogg , Pilarski, Robert , Blanco, Amie , Woodson, Ashley, Taplin, Mary-Ellen, Polascik, Thomas J. , Hyatt, Colette, Feng, Felix Y. , Mullane, Michael P., Powers, Jacqueline, Concepcion, Raoul S. , Lin, Daniel W. , Wender, Richard C. , Mark, James Ryan , Costello, Anthony J. , Isaacs, William B. , Xu, Jianfeng , Weitzel, Jeffrey N. , Andriole, Gerald L. , Beltran, Himisha , Briganti, Alberto , Byrne, Lindsey , Calvaresi, Anne, Chandrasekar, Thenappan , Chen, David Y.T. , Dobi, Albert , Crawford, E. David , Eastham, James A., Eggener, Scott E. , Freedman, Matthew L. , Garnick, Marc B. , Gomella, Patrick T. , Handley, Nathan , Hurwitz, Mark , Izes, Joseph K. , Karnes, R. Jeffrey , Lallas, Costas D. , Languino, Lucia R. , Loughlin, Kevin R. , Lu‐Yao, Grace , Malkowicz, S. Bruce, Mann, Mark, Mille, Patrick , Miner, Martin , Morgan, Todd M. , Mucci, Lorelei A. , Nielsen, Sarah M. , O’Neil, Brock , Pinover, Wayne H., Pinto, Peter A. , Poage, Wendy, Raj, Ganesh V. , Ryan, Charles J. , Schiewer, Matthew J. , Szymaniak, Brittany M. , Tester, William , Trabulsi, Edouard J. , Vapiwala, Neha , Gomella, Leonard G. , Weitzel, Jeffrey N , Morgan, Todd M , Cheng, Heather H , Dicker, Adam P , Giri, Veda N. , Knudsen, Karen E. , Cooney, Kathleen A. , Toland, Amanda Ewart , Pritchard, Colin C. , Carroll, Peter R , Rahm, Alanna Kulchak , Taplin, Mary‐Ellen , Helfand, Brian T. , Morgans, Alicia K. , Burnett, Arthur L. “Bud” , Sartor, Oliver , Den, Robert B. , Loeb, Stacy , López, Ana María , Moreno, Jose, Myers, Ronald E. , Rebbeck, Timothy R. , Sandler, Howard M. , Scott, E. Michael D., Yu, Evan Y , Zeigler-Johnson, Charnita M

Mayo Clinic

Journal of Clinical Oncology | June 9, 2020 | Volume: 38 | Issue: 24 | Pages: 2798-2811

10.1200/jco.20.00046 | PMID 32516092 Get It

PURPOSE Germline testing (GT) is a central feature of prostate cancer (PCA) treatment, management, and hereditary cancer assessment. Critical needs include optimized multigene testing strategies that incorporate evolving genetic data, consistency in GT indications and management, and alternate genetic evaluation models that address the rising demand for genetic services. METHODS A multidisciplinary consensus conference that included experts, stakeholders, and national organization leaders was convened in response to current practice challenges and to develop a genetic implementation framework. Evidence review informed questions using the modified Delphi model. The final framework included criteria with strong (> 75%) agreement (Recommend) or moderate (50% to 74%) agreement (Consider). RESULTS Large germline panels and somatic testing were recommended for metastatic PCA. Reflex testing—initial testing of priority genes followed by expanded testing—was suggested for multiple scenarios. Metastatic disease or family history suggestive of hereditary PCA was recommended for GT. Additional family history and pathologic criteria garnered moderate consensus. Priority genes to test for metastatic disease treatment included BRCA2, BRCA1, and mismatch repair genes, with broader testing, such as ATM, for clinical trial eligibility. BRCA2 was recommended for active surveillance discussions. Screening starting at age 40 years or 10 years before the youngest PCA diagnosis in a family was recommended for BRCA2 carriers, with consideration in HOXB13, BRCA1, ATM, and mismatch repair carriers. Collaborative (point-of-care) evaluation models between health care and genetic providers was endorsed to address the genetic counseling shortage. The genetic evaluation framework included optimal pretest informed consent, post-test discussion, cascade testing, and technology-based approaches. CONCLUSION This multidisciplinary, consensus-driven PCA genetic implementation framework provides novel guidance to clinicians and patients tailored to the precision era. Multiple research, education, and policy needs remain of importance.
Improved relapse recovery in paediatric compared to adult multiple sclerosis
Aaen, Greg, Belman, Anita , Gorman, Mark , Harris, Yolanda, Krupp, Lauren , Lotze, Timothy , Mar, Soe , Ness, Jayne , Schreiner, Teri , Tillema, Jan‐Mendelt , Roalstad, Shelly, Rose, John , Weiner, Howard L. , Casper, T. Charles , Rodriguez, Moses , Krupp, Lauren , Rodriguez, Moses , Chitnis, Tanuja , Aaen, Gregory , Benson, Leslie , Goyal, Manu S. , Graves, Jennifer , Rensel, Mary R. , Schreiner, Teri , Waubant, Emmanuelle L. , Weinstock‐Guttman, Bianca

Mayo Clinic

Brain | June 8, 2020 | Volume: 143 | Issue: 9 | Pages: 2733-2741

10.1093/brain/awaa199 | PMID 32810215 Get It

AbstractIncomplete relapse recovery contributes to disability accrual and earlier onset of secondary progressive multiple sclerosis. We sought to investigate the effect of age on relapse recovery. We identified patients with multiple sclerosis from two longitudinal prospective studies, with an Expanded Disability Status Scale (EDSS) score within 30 days after onset of an attack, and follow-up EDSS 6 months after attack. Adult patients with multiple sclerosis (n = 632) were identified from the Comprehensive Longitudinal Investigations in Multiple Sclerosis at Brigham study (CLIMB), and paediatric patients (n = 132) from the US Network of Paediatric Multiple Sclerosis Centers (NPMSC) registry. Change in EDSS was defined as the difference in EDSS between attack and follow-up. Change in EDSS at follow-up compared to baseline was significantly lower in children compared to adults (P = 0.001), as were several functional system scores. Stratification by decade at onset for change in EDSS versus age found for every 10 years of age, EDSS recovery is reduced by 0.15 points (P < 0.0001). A larger proportion of children versus adults demonstrated improvement in EDSS following an attack (P = 0.006). For every 10 years of age, odds of EDSS not improving increase by 1.33 times (P < 0.0001). Younger age is associated with improved recovery from relapses. Age-related mechanisms may provide novel therapeutic targets for disability accrual in multiple sclerosis.
Rhinologic Practice Special Considerations During COVID‐19: Visit Planning, Personal Protective Equipment, Testing, and Environmental Controls
Howard, Brittany E. , Lal, Devyani

Mayo Clinic

Otolaryngology–Head and Neck Surgery | June 2, 2020 | Volume: 163 | Issue: 4 | Pages: 676-681

10.1177/0194599820933169 | PMID 32484728 Get It

As rhinologists return to practice amid SARS‐CoV‐2, special considerations are warranted given the unique features of their subspecialty. Rhinologist manipulation of nasal tissue, proximity, and frequent aerosol‐generating procedures (AGPs) create high risk for infection transmission. There are 4 areas of special consideration to mitigate risk: (1) previsit planning for risk stratification/mitigation, (2) appropriate personal protective equipment, (3) preprocedural testing, and (4) environmental controls. During previsit planning, risk factors of the patient and procedures are considered. High‐risk AGPs are identified by duration, proximity, manipulation of high–viral load tissue, and use of powered instrumentation. Appropriate personal protective equipment includes selection of respiratory and eye protection. COVID‐19 testing can screen for asymptomatic carriers prior to high‐risk procedures; however, alternative testing methods are required in rhinologic patients not eligible for nasopharyngeal testing due to nasal obstruction or skull base defects. Last, AGPs in rhinologic practices require considerations of room air handling and environmental controls.
Variability in Cytogenetic Testing for Multiple Myeloma: A Comprehensive Analysis From Across the United States
Yu, Yang , Wadé, Niquelle Brown , Hwang, Amie E. , Nooka, Ajay K. , Fiala, Mark A. , Mohrbacher, Ann , Peters, Edward , Pawlish, Karen , Rand, Kristin A. , Conti, David V. , Auclair, Daniel , Mehta, Jayesh, Haiman, Christopher A. , Terebelo, Howard R. , Janakiraman, Nalini, Vij, Ravi , Bernal‐Mizrachi, Leon , Zonder, Jeffrey A. , Huff, Carol Ann , Orlowski, Robert Z. , Brown Wade, Niquelle , Van Den Berg, David J , Auclair, Daniel , Vij, Ravi , Zonder, Jeffrey A , Huff, Carol A , Cozen, Wendy , Ailawadhi, Sikander , Orlowski, Robert Z. , Fiala, Mark A , Nooka, Ajay K , Conti, David V , Yu, Yang, Bock, Cathryn Hufford , Berg, David Van Den , Stram, Daniel O. , Colditz, Graham A. , Singhal, Seema , Chiu, Brian C.‐H. , Lonial, Sagar , Cozen, Wendy , Ailawadhi, Sikander

Mayo Clinic

JCO Oncology Practice | May 29, 2020 | Volume: 16 | Issue: 10 | Pages: e1169-e1180

10.1200/jop.19.00639 | PMID 32469686 Get It

Purpose: Multiple myeloma (MM) treatment has changed tremendously, with significant improvement in patient out-comes. One group with a suboptimal benefit is patients with high-risk cytogenetics, as tested by conventional karyotyping or fluorescence in situ hybridization (FISH). Methodology for these tests has been published, but not necessarily standardized. Methods: We address variability in the testing and reporting methodology for MM cytogenetics in the United States using the ongoing African American Multiple Myeloma Study (AAMMS). We evaluated clinical and cytogenetic data from 1,221 patients (1,161 with conventional karyotyping and 976 with FISH) tested between 1998 and 2016 across 58 laboratories nationwide. Results: Interlab and intralab variability was noted for the number of cells analyzed for karyotyping, with a significantly higher number of cells analyzed in patients in whom cytogenetics were normal (P 5.0025). For FISH testing, CD138-positive cell enrichment was used in 29.7% of patients and no enrichment in 50% of patients, whereas the remainder had unknown status. A significantly smaller number of cells was analyzed for patients in which CD138 cell enrichment was used compared with those without such enrichment (median, 50 v 200; P, .0001). A median of 7 loci probes (range, 1-16) were used for FISH testing across all laboratories, with variability in the loci probed even within a given laboratory. Chromosome 13–related abnormalities were the most frequently tested abnormality (n5956; 97.9%), and t(14;16) was the least frequently tested abnormality (n 5 119; 12.2%). Conclusions: We report significant variability in cytogenetic testing across the United States for MM, potentially leading to variability in risk stratification, with possible clinical implications and personalized treatment approaches.
PROTOCOL: When and how to replicate systematic reviews
Karunananthan, Sathya , Maxwell, Lara , Pardo, Jordi Pardo , Avey, Marc T. , Baptiste-Ngobi, John, Batista, Ricardo , Curran, Janet , Ghogomu, Elizabeth Tanjong , Graham, Ian D. , Ioannidis, John P. A. , Jordan, Zoe , Jull, Janet , Lyddiatt, Anne , Pottie, Kevin , Shamseer, Larissa , Shea, Beverley , Siontis, Konstantinos C. , Tschirhart, Naomi , Wells, George A. , Ioannidis, John P A , Pottie, Kevin , Welch, Vivian Andrea , Petkovic, Jennifer , Rader, Tamara , Batista, Ricardo, Grimshaw, Jeremy , Moher, David , Petticrew, Mark P. , G, Gabriel Rada , Vachon, Brigitte , White, Howard , Tugwell, Peter

Mayo Clinic

Campbell Systematic Reviews | May 28, 2020 | Volume: 16 | Issue: 2 | Pages: No page available

10.1002/cl2.1087 | PMID 37131421 Get It

Abstract This is a protocol for a co‐registered Cochrane and Campbell Review (Methodology). The objectives are as follows: To identify, describe and assess methods for: when to replicate a systematic review; how to replicate a systematic review.
A multicenter phase II study of nivolumab +/- ipilimumab for patients with metastatic sarcoma (Alliance A091401): Results of expansion cohorts.
Chen, James Lin, Mahoney, Michelle R., Tine, Brian Andrew Van, Tap, William D. , Streicher, Howard , George, Suzanne , Antonescu, Cristina R. , Liebner, David A. , Milhem, Mohammed , Schwartz, Gary K. , D'Angelo, Sandra P

Mayo Clinic

Journal of Clinical Oncology | May 25, 2020 | Volume: 38 | Issue: 15_suppl | Pages: 11511-11511

10.1200/jco.2020.38.15_suppl.11511 Get It

11511 Background: In the open-label multicenter phase II study, A091401, nivolumab (N) and nivolumab+ipilimumab (N+I) demonstrated a confirmed response rate (RR) of 5% and 16%, respectively in patients (pts) with advanced sarcoma (D’Angelo SP et al Lancet Oncology 2018). Responses occurred in undifferentiated pleomorphic sarcoma (UPS), myxofibrosarcoma, leiomyosarcoma, sarcoma not otherwise specified and alveolar soft part sarcoma. Here, we report efficacy of N and N+I, in each of 3 expansion cohorts [gastrointestinal stromal tumor (GIST), UPS and dedifferentiated liposarcoma (DDLS)]. Methods: Pts refractory to ≥ 1 regimen(s) were randomized (non-comparative) to receive either N [N (3 mg/kg q2W)] or N+I [N (3 mg/kg Q3W x4, then Q2W) plus I (3 mg/kg q3W x4)]. The primary endpoint was 6 month confirmed RR (RECIST v1.1). For UPS and DDLS, 2 confirmed responses in the 1st 12 evaluable pts was needed (85% power, 1-sided alpha=0.15, 5 v 25% RR). For GIST, a confirmed response in the 1st 9 evaluable pts expanded enrollment to 24 (80% power, 1-sided alpha=0.10, 5 v 20% RR). Other endpoints: adverse events (AEs, TRAEs), progression-free and overall survival (PFS, OS), and correlatives. Results: See table. Clinical trial information: NCT02500797 . Conclusions: Neither N or N+I lead to confirmed responses in GIST. In DDLS and UPS, the primary response endpoint was met with N+I but not with N alone (RR 14% for N+I vs. 7% and 8% for N alone). For the GIST cohort TRAE was higher with N+I, holding enrollment as required per protocol. There remains a pressing need to determine genomic and clinical biomarkers of response, resistance and toxicity. Correlative analyses (whole exome sequencing, multiplex IHC and RNAseq) are in progress. Support: U10CA180821, U10CA180882; ClinicalTrials.gov Identifier: NCT02500797. [Table: see text]
Impact of lenalidomide-bortezomib-dexamethasone (RVd) induction on patients with newly diagnosed multiple myeloma and renal impairment: Results from the Connect MM Registry.
Lee, Hans Chulhee, Omel, Jim, Toomey, Kathleen, Gasparetto, Cristina , Rifkin, Robert M. , Durie, Brian G.M. , Narang, Mohit , Terebelo, Howard R. , Dhalla, Mazaher, Mia, HE, Srinivasan, Shankar , Robinson, Suzanne, Abonour, Rafat , Ailawadhi, Sikander , Lee, Hans C. , Hardin, James W. , Jagannath, Sundar , Wagner, Lynne I. , Joshi, Prashant Ramesh

Mayo Clinic

Journal of Clinical Oncology | May 25, 2020 | Volume: 38 | Issue: 15_suppl | Pages: 8518-8518

10.1200/jco.2020.38.15_suppl.8518 Get It

8518 Background: Patients (pts) with newly diagnosed multiple myeloma (NDMM) and renal impairment (RI) are often excluded from clinical trials. Data are limited on the effects of induction treatment in these pts, who may also be ineligible for autologous stem cell transplant (SCT) due to severity of RI. This analysis investigated the impact of RVd induction on renal function in transplant eligible (TE) and noneligible (TNE) pts from the Connect MM Registry, a US, multicenter, prospective, observational study. Methods: Eligible pts were ≥ 18 y and had symptomatic MM diagnosed ≤ 2 mos prior to enrollment, as defined by the International Myeloma Working Group criteria. For this analysis, pts that received front-line RVd for ≥ 3 cycles were grouped per transplant eligibility and renal function at baseline (BL; creatinine clearance [CrCl] < 30, 30-50, > 50-80, and > 80). Pts with progressive disease at BL were excluded. Renal function at 3 mos was measured. Median unadjusted progression-free survival (PFS) was calculated from start of regimen in TE and TNE populations, with pts grouped by CrCl (≤ 60 or > 60) at BL. Results: As of 7/23/19, 421 TE and 212 TNE pts received RVd for ≥ 3 cycles. TE and TNE pts were grouped by BL CrCl of < 30 (20 and 16 pts), 30-50 (36 and 50 pts), > 50-80 (117 and 63 pts), and > 80 (248 and 83 pts). Renal function improvement was observed in all pts receiving RVd, including those with moderate (30-50 CrCl) and severe (< 30 CrCl) RI at BL (Table). In pts with > 60 CrCl and ≤ 60 CrCl at BL, median PFS in TE pts was 48.6 mos and 43.2 mos, respectively. In TNE pts, median PFS was 36.4 mos and 30.6 mos, respectively. Conclusions: The results from the Connect MM Registry indicate that pts with NDMM and RI (including moderate and severe) who receive front-line RVd for ≥ 3 cycles may see improvement in renal function at 3 mos, regardless of transplant eligibility. RVd therefore can potentially be used in pts with RI. This analysis provides real-world data that support further investigation of RVd treatment in pts with moderate or severe RI. Clinical trial information: NCT01081028 . [Table: see text]
Short-term adjuvant versus neoadjuvant hormone therapy in localized prostate cancer: A pooled individual patient analysis of two phase III trials.
Malone, Shawn , Roy, Soumyajit , Grimes, Scott, Eapen, Libni , Malone, Julia, Craig, Julia , Dess, Robert T. , Schipper, Matthew J. , Michalski, Jeff M. , Pisansky, Thomas M. , Feng, Felix Y. , Shipley, William U. , Roach, Mack , Lawton, C.A., Dess, Robert T , Spratt, Daniel E. , Morgan, Scott C. , Jackson, Will , Lee, W. Robert , Sandler, Howard M. , Sun, Yilun

Mayo Clinic

Journal of Clinical Oncology | May 25, 2020 | Volume: 38 | Issue: 15_suppl | Pages: 5584-5584

10.1200/jco.2020.38.15_suppl.5584 Get It

5584 Background: The timing of systemic therapy in relation to radiotherapy (RT) is important in most malignancies. In contrast, androgen deprivation therapy (ADT) has largely been investigated in relation to its duration rather than its sequencing with RT. Herein, we conduct the first combined individual patient analysis of two phase III randomized trials to determine the optimal timing of ADT with RT in localized prostate cancer (PCa). Methods: Individual patient data was obtained from the Malone et al trial (JCO 2019), which randomized patients to receive neoadjuvant/concurrent or concurrent/adjuvant ADT for 6 months with prostate only RT. This was combined with the prostate only RT arms of RTOG 9413 that randomized patients to 4 months of neoadjuvant/concurrent or adjuvant ADT. The neoadjuvant/concurrent arms of both trials were combined into the “neoadjuvant” group, and the concurrent/adjuvant (Malone) and adjuvant arm (RTOG 9413) were combined in the “adjuvant” group. The Kaplan-Meier method was used to estimate overall survival (OS) and progression-free survival (PFS). Cumulative incidence of distant metastasis (DM), PCa-specific mortality (PCSM) and biochemical failure (BF) were calculated using the Fine-Gray method with non-PCa deaths as competing events. Late genitourinary (GU) and gastrointestinal (GI) toxicity are also reported. Results: The median follow-up was 14.9 years (yrs) and 1065 patients were included (n=531 neoadjuvant, 534 adjuvant). Groups were well balanced for all baseline characteristics. Adjuvant ADT was superior to neoadjuvant ADT in terms of BF (15yr: 33% vs 43%, HR: 1.37 (95%CI: 1.12-1.68), p=0.002), DM (15yr: 12% vs 18%, HR: 1.40 (95%CI: 1.00-1.95), p=0.04), and PFS (15yr: 36% vs 29%, HR: 1.25 (95%CI: 1.07-1.47), p=0.01). Adjuvant ADT yielded lower PCSM (15yr: 15% vs 20%, HR: 1.29 (95%CI: 0.95-1.75), p=0.10), but did not reach statistical significance. This approached statistical significance in high risk PCa (HR 1.39 (95%CI 1.00-1.93), p=0.053). OS was not significantly different between arms (15yr: 39% vs 34%, HR: 1.11 (95%CI: 0.95-1.30), p=0.20). There was no significant difference in either late grade ≥3 GI (p=0.21) or GU (p=0.98) toxicity. Conclusions: We demonstrate for the first time that sequencing of ADT with RT significantly impacts long-term oncologic outcomes in localized PCa, favoring an adjuvant rather than neoadjuvant approach, without increasing late toxicity. This data has important implications to ongoing and future clinical trial design. Clinical trial information: NCT00769548 .
Trastuzumab with trimodality treatment for esophageal adenocarcinoma with HER2 overexpression: NRG Oncology/RTOG 1010.
Safran, Howard , Winter, Kathryn, Wigle, Dennis A. , DiPetrillo, Thomas A., Haddock, Michael G. , Hong, Theodore S. , Leichman, Lawrence P., Rajdev, Lakshmi , Resnick, Murray B. , Kachnic, Lisa A. , Mamon, Harvey J. , Pardo, D.A. Diaz, Salo, Jonathan C. , Leonard, K.L. , Crane, Christopher H. , Seaward, Samantha A , Anderson, Carryn M. , Shen, Xinglei , Sharma, Anand K. , Katz, Alan W.

Mayo Clinic

Journal of Clinical Oncology | May 25, 2020 | Volume: 38 | Issue: 15_suppl | Pages: 4500-4500

10.1200/jco.2020.38.15_suppl.4500 Get It

4500 Background: Trastuzumab is a monoclonal antibody against human epidermal growth factor receptor 2 (HER2). The primary objective of RTOG 1010 was to determine if trastuzumab increases disease-free survival (DFS) when combined with trimodality treatment for patients with HER2 overexpressing esophageal adenocarcinoma. Methods: This open label, randomized phase III trial included patients with newly diagnosed stage T1N1-2, T2-3N0-2 adenocarcinoma of the esophagus involving the mid, distal, or esophagogastric junction and up to 5cm of the stomach. All patients received chemotherapy (C) of paclitaxel, 50mg/m2 and carboplatin AUC = 2, weekly for 6 weeks, with radiation (XRT: 3D-CRT or IMRT, 50.4 Gy in 28 fractions) followed by surgery. Patients were randomized 1:1 to receive weekly trastuzumab 4mg/kg week 1 then 2mg/kg/weekly x 5 during CXRT then 6 mg/kg for 1 dose prior to surgery and 6mg/kg every 3 weeks for 13 treatments after surgery. HER2 status was determined by IHC and gene amplification by FISH. With a 2-sided alpha of 0.05, 162 DFS events provide 90% power to detect a signal for an increase in median DFS from 15 to 25 months. DFS and overall survival (OS) were estimated by the Kaplan-Meier method. and arms were compared using the log rank test. The Cox proportional hazards model was used to analyze treatment effect. Results: 571 patients were entered for assessment of HER2 expression, 203 HER2+ patients randomized. The median follow-up for alive patients is 5.0 years. The estimated 2, 3, and 4-year DFS (95% CI) for the CXRT +trastuzumab arm were 41.8% (31.8%, 51.7%), 34.3% (24.7%, 43.9%), and 33.1% (23.6%, 42.7%), respectively, and for the CXRT arm were 40.0% (30.0%, 49.9%), 33.4% (23.8%, 43.0%), and 30.1% (20.7%, 39.4%), respectively; log-rank p = 0.85. The median DFS time is 19.6 months (13.5-26.2) for the CXRT +trastuzumab arm compared to 14.2 months (10.5-23.0) for the CXRT arm. The hazard ratio (95% CI) comparing the DFS of CXRT+trastuzumab arm to the CXRT arm was 0.97 (0.69, 1.36). The median OS time was 38.5 months (26.2-70.4) for the CXRT+trastuzumab arm compared to 38.9 months (29.0-64.5) for the CXRT arm, hazard ratio (95% CI): 1.01 (0.69, 1.47). There was no statistically significant increase in treatment-related toxicities with the addition of trastuzumab including no increase in cardiac events. Conclusions: The addition of trastuzumab to trimodality treatment did not improve DFS for patients with HER2 overexpressing esophageal adenocarcinoma. Supported by NCI grants U10CA180868, UG1CA189867, U10CA180822 and Genentech. Clinical trial information: NCT01196390 .